Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xavier Paoletti

Showing results (1-10 of 145) with videos related to

Pageof 15
Sort By:
Bulletin Du Cancer|December 7, 2007
[Interim analyses]Andrew Kramar, Xavier Paoletti
Surgical Oncology|February 20, 2010
Survival analysis in clinical trials: old tools or new techniquesXavier Paoletti, Bernard Asselain
Biometrics|August 21, 2003
Continual reassessment method for ordered groupsJohn O'Quigley, Xavier Paoletti
Statistical Methods in Medical Research|April 5, 2019
An adaptive design for the identification of the optimal dose using joint modeling of continuous repeated biomarker measurements and time-to-toxicity in phase I/II clinical trials in oncologyMaria-Athina Altzerinakou, Xavier Paoletti
Statistics in Medicine|February 9, 2021
Change-point joint model for identification of plateau of activity in early phase trialsMaria-Athina Altzerinakou, Xavier Paoletti
International Journal of Cancer|June 12, 2003
Induced and spontaneous abortion and breast cancer risk: results from the E3N cohort studyXavier Paoletti, Françoise Clavel-Chapelon
Journal of Biopharmaceutical Statistics|October 24, 2018
Randomized dose-escalation designs for drug combination cancer trials with immunotherapyPavel Mozgunov, Thomas Jaki, Xavier Paoletti
Biostatistics (Oxford, England)|January 7, 2021
A benchmark for dose-finding studies with unknown orderingPavel Mozgunov, Xavier Paoletti, Thomas Jaki
Computer Methods and Programs in Biomedicine|March 8, 2018
surrosurv: An R package for the evaluation of failure time surrogate endpoints in individual patient data meta-analyses of randomized clinical trialsFederico Rotolo, Xavier Paoletti, Stefan Michiels
Statistics in Medicine|September 11, 2013
Dose-finding design using mixed-effect proportional odds model for longitudinal graded toxicity data in phase I oncology clinical trialsAdélaïde Doussau, Rodolphe Thiébaut, Xavier Paoletti
Pageof 15

Showing results (1-10 of 145) with videos related to

Sort By:
Pageof 15
Bulletin Du Cancer|December 7, 2007
[Interim analyses]Andrew Kramar, Xavier Paoletti
Surgical Oncology|February 20, 2010
Survival analysis in clinical trials: old tools or new techniquesXavier Paoletti, Bernard Asselain
Biometrics|August 21, 2003
Continual reassessment method for ordered groupsJohn O'Quigley, Xavier Paoletti
Statistical Methods in Medical Research|April 5, 2019
An adaptive design for the identification of the optimal dose using joint modeling of continuous repeated biomarker measurements and time-to-toxicity in phase I/II clinical trials in oncologyMaria-Athina Altzerinakou, Xavier Paoletti
Statistics in Medicine|February 9, 2021
Change-point joint model for identification of plateau of activity in early phase trialsMaria-Athina Altzerinakou, Xavier Paoletti
International Journal of Cancer|June 12, 2003
Induced and spontaneous abortion and breast cancer risk: results from the E3N cohort studyXavier Paoletti, Françoise Clavel-Chapelon
Journal of Biopharmaceutical Statistics|October 24, 2018
Randomized dose-escalation designs for drug combination cancer trials with immunotherapyPavel Mozgunov, Thomas Jaki, Xavier Paoletti
Biostatistics (Oxford, England)|January 7, 2021
A benchmark for dose-finding studies with unknown orderingPavel Mozgunov, Xavier Paoletti, Thomas Jaki
Computer Methods and Programs in Biomedicine|March 8, 2018
surrosurv: An R package for the evaluation of failure time surrogate endpoints in individual patient data meta-analyses of randomized clinical trialsFederico Rotolo, Xavier Paoletti, Stefan Michiels
Statistics in Medicine|September 11, 2013
Dose-finding design using mixed-effect proportional odds model for longitudinal graded toxicity data in phase I oncology clinical trialsAdélaïde Doussau, Rodolphe Thiébaut, Xavier Paoletti
Pageof 15